Fig. 8.
Long-term deletion of Sirt6 in beta cells induces susceptibility to STZ. (aImmunoblots of TXNIP, H3K9Ac and H3K56Ac in islets isolated from 2-month-old and 7-month-old control (Ctrl, Sirt6f/f and Sirt6 EKO mice, (b) Representative H&E staining of pancreases from 11-month-old control and Sirt6 EKO mice. Scale bar, 1 mm. (c) Quantification of the mass of the islet area in ((b). (d) Blood glucose levels in 2-month-old male control and Sirt6 EKO mice after a single STZ treatment (75 mg/kg), (e) Plasma insulin levels in 2-month-old male control and Sirt6 EKO mice 2 days after a single STZ treatment, (f) Blood glucose levels in 7-month-old control and Sirt6 EKO mice after a single STZ treatment (75 mg/kg) (n=6). (g) Plasma insulin levels of 7-month-old control and Sirt6 EKO mice 2 days after a single STZ treatment, (h) Immunostaining of pancreases from 7-month-old control and Sirt6 EKO mice 2 days after a single STZ treatment. Green, anti-insulin; red, anti-cleaved caspase 3; blue, DAPI. Scale bar, 50 μm. (i) Representative H&E staining and immunostaining of pancreases from 7-month-old control and Sirt6 EKO mice 4 days after a single STZ treatment. Green, anti-insulin; red, antiglucagon; blue, DAPI. Scale bar, 50 μm. (j) Quantification of the insulin-positive area of 7-month-old control and Sirt6 EKO mice 4 days after a single STZ treatment. Black bars and circles, control mice; grey bars and squares, Sirt6 EKO mice. Data are expressed as means ± SEM (n=3 or 4, unless stated otherwise). *p<0.05 and **p<0.01 vs control condition or for indicated comparisons